In January 2026, the U.S. Food and Drug Administration (FDA) took a meaningful step toward modernizing how we generate evidence in drug development. It issued a draft guidance specifically focused on using Bayesian methodology to support primary inference in clinical trials. The FDA is essentially saying: when done rigorously, Bayesian methods can be fit-for-purpose for confirmatory questions, not just...